NCT01316601View on ClinicalTrials.gov

A Study to Assess Efficacy, Safety and Tolerability of the Anti-IL-13 Monoclonal Antibody QAX576 in the Treatment of Perinanal Fistulas in Patients Suffering From Crohn's Disease

PHASE2CompletedINTERVENTIONAL

Enrollment

3

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions

Crohn's Disease

Interventions

DRUG

QAX567

Trial Locations (1)

Unknown

Zurich

Sponsors

Collaborators (1)

Novartis Pharmaceuticals

All Listed Sponsors

collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Gerhard Rogler

OTHER

NCT01316601 - A Study to Assess Efficacy, Safety and Tolerability of the Anti-IL-13 Monoclonal Antibody QAX576 in the Treatment of Perinanal Fistulas in Patients Suffering From Crohn's Disease | Biotech Hunter | Biotech Hunter